title: Designer antiandrogens join the race against drug resistance.
abstract: By using in silico models of the complexes formed by analogues of a cancer drug and its receptor, it may be possible to strategically redesign existing drugs and win the race against mutations that lead to drug resistance in prostate cancer.
authors.affiliation: is at the Department of Chemistry , University of Illinois at Urbana-Champaign , Urbana , United States jsjosan@illinois.edu.
authors.forename: Jatinder S
authors.initials: JS
authors.lastname: Josan
authors.forename: John A
authors.initials: JA
authors.lastname: Katzenellenbogen
mesh_terms: D000726:Androgen Antagonists / Q000627:therapeutic use*; D015195:Drug Design; D006801:Humans; D008297:Male; D009154:Mutation
chemical_list: D000726:Androgen Antagonists
keywords: Human; Mouse; androgen receptor; drug resistance; prostate cancer